<DOC>
	<DOCNO>NCT00387790</DOCNO>
	<brief_summary>This phase II trial study well give motexafin gadolinium together radiation therapy work treat young patient pontine glioma . Radiation therapy use high-energy x-ray kill tumor cell . Drugs , motexafin gadolinium , may make tumor cell sensitive radiation therapy . Giving motexafin gadolinium together radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Motexafin Gadolinium Radiation Therapy Treating Young Patients With Pontine Glioma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Evaluate effect combine motexafin gadolinium daily fractionate radiotherapy 1-year event-free survival pediatric patient intrinsic pontine glioma ( brain stem glioma ) . SECONDARY OBJECTIVES : I . Evaluate effect combine motexafin gadolinium daily fractionate radiotherapy 1-year overall survival patient . II . Determine toxicities motexafin gadolinium combination radiotherapy patient . OUTLINE : This multicenter study . Patients receive motexafin gadolinium IV 5-10 minute daily ( prior radiotherapy ) 5 day week 6 week . Patients undergo focal cranial radiotherapy daily 5 day week 6 week . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 3 year periodically thereafter .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>Diagnosis intrinsic pontine glioma ( brain stem glioma ) Clinical radiographic ( MRI ) evidence tumor diffusely involve brain stem ( i.e. , tumor intrinsically [ &gt; 50 % intraaxial ] involve pons pons medulla , pons midbrain , entire brain stem ) allow Tumor may contiguously involve thalamus upper cervical cord No 1 lesion/mass present diagnosis Karnofsky performance status ( PS ) 60100 % ( age &gt; 16 year ) OR Lansky PS 60100 % ( age ≤ 16 year ) Life expectancy ≥ 8 week Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ ( transfusion independent ) Hemoglobin ≥ 10 g/dL ( RBC transfusion allow ) Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine normal age/gender ( 0.41.7 mg/dL ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 1.5 time ULN No known glucose6phosphate dehydrogenase ( G6PD ) deficiency If family history suggestive congenital hemolytic anemia , patient must screen G6PD G6PD activity test prior study entry No biliary obstruction Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior definitive therapy specific tumor No prior cranial radiotherapy Concurrent steroids anticonvulsant allow No concurrent proton therapy No concurrent intensitymodulated radiotherapy No concurrent anticancer chemotherapy No concurrent immunomodulating agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>